Last reviewed · How we verify
Ketorolac at low dose
At a glance
| Generic name | Ketorolac at low dose |
|---|---|
| Also known as | Ketorolac Tromethamine |
| Sponsor | Tianjin Medical University General Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Akathisia
Key clinical trials
- Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients (PHASE4)
- Initial Pain Management in Pediatric Pancreatitis: Opioid vs. Non-Opioid (PHASE2)
- Comparison of Ketorolac at Three Doses in Children With Acute Pain (PHASE3)
- A Pilot Clinical Trial of a New Neuromodulation Device for Acute Attacks of Migraine in Children and Adolescents (PHASE3)
- Opioid Free vs. Standard Perioperative Pain Regimen for Anterior Cervical Discectomy and Fusion (ACDF) Surgery (PHASE4)
- Steroids in Total Knee Arthroplasty (PHASE4)
- Esketamine vs. Ketorolac for Prevention of Postoperative Pain and Cognitive Dysfunction After Total Knee Arthroplasty (NA)
- Different Modalities of Analgesia in Open Heart Surgeries in Mansoura University (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketorolac at low dose CI brief — competitive landscape report
- Ketorolac at low dose updates RSS · CI watch RSS
- Tianjin Medical University General Hospital portfolio CI